Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Elicio Therapeutics’ SEC filings can feel like decoding a clinical protocol. Every 10-K is packed with trial design details, patent diagrams and dilution math that even seasoned analysts find taxing. If you have ever searched “Elicio Therapeutics SEC filings explained simply” or wondered where to locate “Elicio Therapeutics quarterly earnings report 10-Q filing,” this page was built for you.
Stock Titan pairs biotech expertise with AI to break down the language, surface the numbers and highlight what matters. Our engine delivers real-time alerts the moment an “Elicio Therapeutics Form 4 insider transactions real-time” notice hits EDGAR and writes plain-English briefs so you are understanding Elicio Therapeutics SEC documents with AI, not skimming 200 pages.
- 10-K & 10-Q: See R&D spend trends, cash runway and trial milestone timelines in an “Elicio Therapeutics annual report 10-K simplified” or bite-sized “Elicio Therapeutics earnings report filing analysis.”
- Form 4: Track “Elicio Therapeutics insider trading Form 4 transactions” and deeper “Elicio Therapeutics executive stock transactions Form 4” to spot alignment between management and shareholders.
- 8-K: Get concise alerts when an “Elicio Therapeutics 8-K material events explained” filing announces new data, financings or partnerships.
- DEF 14A: Review the “Elicio Therapeutics proxy statement executive compensation” section without wading through compensation tables.
Beyond lists of documents, our AI highlights potential dilution triggers, KRAS vaccine trial updates, and AMP platform IP developments—insights that directly shape valuation. Whether you ask, “How do I read Elicio Therapeutics’ 10-K?” or need instant context before the market opens, you will find every ELTX disclosure here—already clarified.
Actyus Private Equity SGIIC, S.A. filed a Schedule 13G/A reporting beneficial ownership of 268,564 shares of Elicio Therapeutics, Inc. common stock, representing
Elicio Therapeutics, Inc. (ELTX) filed a Form 8-K reporting a material event and included three exhibits: a press release dated
The filing supplies named exhibits that investors can review for trial details and corporate messaging; the 8-K itself does not disclose additional numerical trial outcomes in the provided excerpt, so readers should consult the attached press release, presentation, and Exhibit 99.2 for complete data.
Elicio Therapeutics reported that follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 were published in the peer-reviewed journal Nature Medicine. The company issued a press release announcing the publication, which is attached to this report as Exhibit 99.1 and incorporated by reference. The filing identifies the company as a Delaware corporation with common stock trading under the ticker ELTX on The Nasdaq Capital Market. This disclosure is limited to the publication notice and the inclusion of the press release as an exhibit; no financial results, trial outcomes, or operational actions are presented within the report.
FAQ
What is the current stock price of Elicio Therapeutics (ELTX)?
What is the market cap of Elicio Therapeutics (ELTX)?
